no
ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It’s
notable
to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.”
In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts (Part C) at 200mg (n=9) and 400mg (n=6) daily and in a dose expansion cohort (Part D; n=30) at 200mg daily, all in combination with a standard dose of palbociclib. Eligible patients included post-menopausal women with ER+/HER2- MBC who were pre-treated with endocrine therapy in the advanced setting for at least six months or had resistance to adjuvant endocrine therapy.
Sanofi: Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Immutep Limited Rise on Positive Breast Cancer Data”
Immutep Limited (NASDAQ: IMMP) opened 224% higher than its previous close after announcing that its Chinese partner, EOC Pharma is to commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.
The trial will evaluate Immutep’s lead product candidate eftilagimod alpha in combination with paclitaxel in HER2-negative/HR positive metastatic breast cancer patients.
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients.